Contact Shop

Indirect immunostaining of PFA-fixed, paraffin embedded mouse brain olfactory bulb section with recombinant anti-SARS-CoV-2 Spike antibody (N3583) (dilution 10 µg/mL). Secondary reagent biotinylated anti-rabbit (Jackson 712-065-153) and visualized by ABC Kit HRP Standard (Vector PK-4000).
Nuclei have been visualized by haematoxylin staining (blue).​

 N3583_antiSARS_CoV_2_Spike_S1

Widefield and dSTORM images of SARS-CoV-2 particles produced in Calu-3 cells. Following 4% PFA fixation of infected cells, virions were stained with the recombinant anti-SARS-CoV-2 Spike protein S1 antibody (Cat. No. N3583, dilution 1:200) and detected with secondary anti-rabbit F(ab’)2 antibody. Image courtesy of Maja Klevanski, Institute for Anatomy and Cell Biology, Heidelberg University, Germany.
N3583_antiSARS_CoV_2_Spike_S1

Recombinant anti-SARS-CoV-2 Spike protein S1 antibody (rHcAb)

Cat No: N3583 Category:

420,00 €

The recombinant heavy-chain anti-SARS-CoV-2 Spike protein S1 antibody is a genetic fusion of the single-domain antibody (sdAb) anti-SARS-CoV-2 Spike protein S1 to a Rabbit IgG Fc domain.

Read more

The recombinant heavy-chain anti-SARS-CoV-2 Spike protein S1 antibody is a genetic fusion of the single-domain antibody (sdAb) anti-SARS-CoV-2 Spike protein S1 to a Rabbit IgG Fc domain. This bivalent tool binds the SARS-CoV-2 RBD domain of the S1 protein with high affinity and is ideally suited for ELISA and IHC staining. The fused Rabbit Fc enables researchers to employ conventional secondary detection tools commonly used in automated high-throughput-screening devices. The recombinant heavy-chain antibody (rHcAb) preserves all the biophysical features of the high-affinity binding of the anti-S1 SARS-CoV-2 single-domain antibody and is also capable of neutralizing infections by competing with ACE-2 receptor binding as previously demonstrated by the team of Alejandro Rojas-Fernandez at the Institute of Medicine from the Universidad Austral de Chile. Our anti-S1 SARS-CoV-2 sdAb binds to the S1 protein and is able to neutralize the virus entry by blocking the interaction between RDB and the cell surface-exposed receptor.

SARS-Cov-2 Spike S1 Coronaviruses form trimers with the spike glycoprotein (S) to bind its receptor, mediate membrane fusion, and result in the virus entry. Each spike glycoprotein monomer S is about 180 kDa and contains two subunits, the S1 and S2, mediating attachment and membrane fusion, respectively. The S1 subunit of S protein folds in 2 main domains, the N-terminus domain (NTD) and the receptor-binding domain (RBD), which is responsible for binding a surface protein on mammalian cells.

MSDS
Protocols
Reconstitution and Storage
Variations:
Conjugation Amount Cat No. RRID
Rabbit IgG Fc-fusion 100 µg N3583 AB_3076093
Related Products:

FluoTag®-Q anti-SARS-CoV-2 Spike protein S1 (Cat. No. N3501)

sdAb anti-SARS-CoV-2 Spike protein S1 (Cat. No. N3505)

View related products
Clone: W25
Host: Alpaca
Produced in: HEK
Application: IF, IHC
Dilution: 1:500 (IF), 10 µg/mL (IHC), 1:1000 ELISA
Capacity: N/A
Antigen: -
Targets: SARS-CoV-2 S1
Specificity: Recognizes the RBD of the SARS-CoV-2 S1 protein.
Formulation:

Lyophilized from PBS pH 7.4. Reconstitute with 100 µL 50% glycerol (v/v) in deionized water. If applicable, we recommend including 0.1% sodium azide as a preservative. For more details, click the Protocols button above and check Reconstitution and Storage.
kDa: -
Ext Coef: -
Shipping: Ambient temperature
Storage:

Vials containing lyophilized reagent can be stored at 2-8°C for up to 12 months. After reconstitution, store at -80°C for up to 6 months. Working aliquots can be stored at -20°C for up to 4 weeks. For more details, click the Protocols button above and check Reconstitution and Storage.
Protocols:

Relevant protocols can be found under the Protocols button above. For additional information, visit our Resources page.
References:
  1. Klevanski M, Kim H, Heilemann M, Kuner T, Bartenschlager R. Glycan-directed SARS-CoV-2 inhibition by leek extract and lectins with insights into the mode-of-action of Concanavalin A. Antiviral Res. Published online March 5, 2024. doi:10.1016/j.antiviral.2024.105856 (IF, dSTORM; SARS-CoV-2-infected A549-ACE2 and Calu-3 cells)
Notice: To be used in vitro/ for research only. Non-toxic, non-hazardous, non-infectious.
Legal terms:

By purchasing this product you agree to our general terms and conditions.

Limited Use Label License: Internal Research Use Only
The materials you will receive/have received from NanoTag Biotechnologies GmbH (“Materials”) were provided or produced under a service license between NanoTag Biotechnologies GmbH and Life Technologies Corporation, a part of Thermo Fisher Scientific, Inc., (“Life Technologies”) through the use of Life Technologies proprietary cell lines. The only right conveyed to you with respect to the Materials is the limited, non-transferable right to use the Materials to perform internal research for your sole benefit. Pharmacokinetic and toxicology studies required to meet the regulations for filing an IND (“IND-Enabling Studies”), first in human research, and/or first in patient research are expressly excluded from the rights provided. No right to resell the Materials, or any portion or component thereof, is conveyed expressly, by implication, or by estoppel. The Materials are not for use in commercial research (beginning at IND-Enabling Studies and thereafter) or any other commercial purposes or applications of any kind, including, without limitation, quality control and commercial services such as reporting the results of your activities for a fee or other form of consideration. For information on obtaining additional rights, please contact outlicensing@thermofisher.com or Out Licensing, Life Technologies, 5823 Newton Drive, Carlsbad, California 92008.